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Abstract
Background: Structural rearrangements form a major class of somatic variation in cancer genomes. Local
chromosome shattering, termed chromothripsis, is a mechanism proposed to be the cause of clustered
chromosomal rearrangements and was recently described to occur in a small percentage of tumors. The
significance of these clusters for tumor development or metastatic spread is largely unclear.
Results: We used genome-wide long mate-pair sequencing and SNP array profiling to reveal that chromothripsis is
a widespread phenomenon in primary colorectal cancer and metastases. We find large and small chromothripsis
events in nearly every colorectal tumor sample and show that several breakpoints of chromothripsis clusters and
isolated rearrangements affect cancer genes, including NOTCH2, EXO1 and MLL3. We complemented the structural
variation studies by sequencing the coding regions of a cancer exome in all colorectal tumor samples and found
somatic mutations in 24 genes, including APC, KRAS, SMAD4 and PIK3CA. A pairwise comparison of somatic
variations in primary and metastatic samples indicated that many chromothripsis clusters, isolated rearrangements
and point mutations are exclusively present in either the primary tumor or the metastasis and may affect cancer
genes in a lesion-specific manner.
Conclusions: We conclude that chromothripsis is a prevalent mechanism driving structural rearrangements in
colorectal cancer and show that a complex interplay between point mutations, simple copy number changes and
chromothripsis events drive colorectal tumor development and metastasis.
Background
Colorectal cancer develops from a benign adenomatous
polyp into an invasive cancer, which can metastasize to
distant sites such as the liver [1]. Tumor progression is
associated with a variety of genetic changes and chro-
mosome instability often leads to loss of tumor suppres-
sor genes, such as APC, TP53 and SMAD4.
High-throughput DNA sequencing has indicated that
there are between 1, 000 and 10, 000 somatic mutations
in the genomes of adult solid cancers [2-5]. Further-
more, next-generation sequencing has revolutionized
our possibilities to profile genetic changes in cancer
genomes, yielding important insights into the genes and
mechanisms that contribute to cancer development and
progression [5,6]. Systematic sequence analysis of coding
regions in primary and metastatic tumor genomes has
shown that only a few mutations are required to trans-
form cells from an invasive colorectal tumor into cells
that have the capability to metastasize [7]. Similarly,
only two new mutations were identified in a brain
metastasis compared to a primary breast tumor [8].
These data suggest that essential mutations needed for
cancer progression occur predominantly in the primary
tumor genome before initiation of metastasis [9]. In line
with this hypothesis is the finding that distinct clonal
cell populations in primary pancreatic carcinoma can
independently seed distant metastases [10]. However,
marked genetic differences between primary carcinomas
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and metastatic lesions do exist [11], and genotyping of
rearrangement breakpoints in primary and metastatic
pancreatic cancer revealed ongoing genomic evolution
at metastatic sites [12].
In particular, the impact of structural genomic
changes and their contribution to cancer development
have recently received considerable attention [8,13-15].
Many solid tumor genomes harbor tens to hundreds of
genomic rearrangements, which may drive tumor pro-
gression by disruption of tumor suppressor genes, for-
mation of fusion proteins, constitutive activation of
enzymes or amplification of oncogenes [12-17]. Rearran-
gements may be complex, involving multiple inter- and
intra-chromosomal fusions, and often reside in regions
of gene amplification [13,18,19]. Recent genome-wide
copy number profiling of cancer genomes suggests that
2 to 3% of all cancers appear to contain very complex
rearrangements associated with two copy number states
[20,21]. These events involve complete chromosomes or
chromosome arms and are proposed to result from mas-
sive chromosome shattering, termed chromothripsis
[20,21]. The prevalence and impact of such complex
rearrangements in heterogeneous clinical specimens of
solid tumors as well as their relevance for metastasis
formation are currently unclear.
Here, we describe pairwise genomic analyses of
matched primary and metastatic colorectal cancer sam-
ples from four patients using genome-wide mate-pair
sequencing, SNP array profiling and targeted exome
sequencing to explore the genetic changes that consti-
tute colorectal cancer formation and metastasis. We find
marked differences between primary and metastatic
tumors and show that chromothripsis rearrangements
occur frequently in colorectal cancer samples. We con-
clude that chromothripsis events, along with simple
point mutations and structural changes, are major con-
tributors to somatic genetic variation in primary and
metastatic colorectal cancer.
Results and discussion
Patterns of structural variation in primary and metastatic
colorectal tumors
Paired-end sequencing has proven a powerful technique
to profile genomic rearrangements in cancer genomes
[13]. However, there are some limitations associated
with the use of short insert paired-end libraries for
detecting structural variation [22]. Long-insert paired-
end sequencing (also known as long mate-pair sequen-
cing) has the advantage of being able to detect structural
changes across repetitive and duplicated sequences [19].
To study the landscape of structural genomic changes
in fresh tumor samples, we applied genome-wide long
mate-pair sequencing and complementary SNP array
profiling to matching primary and metastatic colorectal
cancer biopsies from four patients (Table 1; Additional
file 1; Materials and methods). Parallel analysis of nor-
mal tissues allowed us to efficiently detect de novo
somatic rearrangements in the genomes of primary and
metastatic lesions. Per sample, we generated between 10
and 65 million mate-pair sequence reads with an aver-
age insert size of 2.5 to 3 kb, resulting in 10× to 48×
average physical genome coverage per sample (Addi-
tional files 2 and 3). We identified 352 somatically
acquired rearrangements in the four patients, including
deletions (177), tandem duplications (39), inversions
(58), and interchromosomal rearrangements (78) (Figure
1a, b; Additional file 4). We independently confirmed
the tumor-specific presence of 222 structural changes by
PCR across the rearrangement breakpoint. Intrachromo-
somal rearrangements were particularly prevalent in our
colorectal tumor samples, similar to what has been
described for other tumor types (Figure 1b) [12,14,16].
Deletion-type rearrangements formed the most common
class of rearrangements, with small deletions (up to 5
kb) being more common than large deletions (Addi-
tional file 5). This is in contrast to primary breast cancer
genomes, for which tandem duplications form the most
common rearrangement class and deletions form the
second largest class [14].
Since we sequenced both primary tumor genomes and
liver metastases as well as control tissue, we could dis-
tinguish between rearrangements that were specific to
both or one of these lesions. For all 222 confirmed rear-
rangements, we performed PCR-based breakpoint
sequencing in primary tumor, metastasis and control
samples (normal liver and normal colon tissue). The
sensitivity of detecting a breakpoint by PCR is below
0.001% and should therefore be a reliable estimate of
the presence of a rearrangement in DNA from a highly
heterogeneous tumor sample [23]. Based on PCR-based
Table 1 Patient overview and tumor status
Patient ID Gender Type Primary tumor grade Metastasis resectiona Treatmentb
Patient 1 Female Adenocarcinoma Moderately differentiated 3 months No treatment
Patient 2 Male Adenocarcinoma Moderately differentiated 20 months No treatment
Patient 3 Male Adenocarcinoma Poorly differentiated 10 months XELOXc and Bevacizumab
Patient 4 Female Adenocarcinoma Well differentiated 9 months 5FU, leucovorin, oxaliplatin, bevacizumab
aTime between primary resection and metastasis resection. bTreatment after primary tumor resection. cCapecitabine and oxaliplatin. 5FU, fluorouracil.
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Figure 1 Rearrangements in colorectal tumors detected by long mate-pair sequencing. (a) Circos plots displaying rearrangements and
their chromosomal locations in primary and metastatic colorectal tumor samples. Rearrangement fusion points and orientations are indicated by
colored links: red, head-head; blue, tail-head; green, head-tail; orange, tail-tail (low coordinate to high coordinate). Chromosome ideograms are
shown on the outer ring. The inner two rings show copy number profiles based on log R ratios derived from SNP array analysis. Red copy
number plots correspond to the liver metastasis and blue plots correspond to the primary tumor. Copy number variation for matching normal
colon and liver tissue are plotted in black. (b) Classes of rearrangements identified in tumors of the four patients. Deletion-type rearrangements
have tail-head orientation, tandem duplication type rearrangements have head-tail orientation and inverted rearrangements have head-head or
tail-tail orientation. (c) Lesion-specific presence of rearrangements in primary and metastatic tumors as based on PCR genotyping of DNA
samples from primary tumor, metastasis and control tissue.
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breakpoint sequencing we found that, depending on the
patient, between 32% and 95% of all rearrangements
were specific to either the primary tumor or the metas-
tasis (Figure 1c). There are several potential explana-
tions for the observed differences between primary and
metastatic sites: (i) changes could have occurred in the
primary tumor and metastasis after dissemination to the
liver; (ii) the part of the primary tumor sample that we
analyzed did not contain the cells that were giving rise
to the metastasis; (iii) metastatic tumor cells may have
lost rearrangements that occurred in the primary tumor;
and (iv) PCR may not be sensitive enough to detect
breakpoints in very low numbers of cells, such as sub-
clones in the primary tumor that may have given rise to
the metastasis [10]. Given the significant overlap in
somatic structural changes between primary tumors and
corresponding metastases (5 to 68%; Figure 1c), we rea-
son that many rearrangements arose in the primary
tumor before metastatic spread. These overlapping rear-
rangements within a patient may represent early somatic
rearrangements within the primary parental clone [10].
Subsequent genomic instability in the metastatic lesion
may have led to additional structural changes on top of
the ones that were found in the primary tumor [12].
The many primary-tumor specific rearrangements likely
arose after dissemination to the liver or were present in
subclones of the primary tumor that did not have the
capability to metastasize. Taken together, our pairwise
comparison of structural changes in colorectal tumors
shows that primary and metastatic colorectal cancer
genomes have rearrangements in common, but also har-
bor distinct patterns of structural variation.
Chromothripsis is a common mechanism driving
structural changes in primary and metastatic colorectal
tumors
Mate-pair sequencing allows identification of rearrange-
ment breakpoints at nucleotide resolution. Furthermore,
mate-pair signatures involved in complex patterns of
structural changes may be used to reconstruct rear-
ranged chromosomes by linking chromosomal fragments
together based on their relative orientation. We have
previously used mate-pair information to resolve a com-
plex chromothripsis event in the germline [24].
Close examination of the landscape of genomic rearran-
gements in primary and metastatic samples revealed chro-
mosomal locations where breakpoints form complex
clusters (Figure 2; Additional file 6). Several mechanisms
may account for the occurrence of complex rearrange-
ments in cancer genomes [18,21,25]. Complex rearrange-
ment patterns have been found in cancer amplicons [18],
which may result from the breakage-fusion-bridge cycle fol-
lowing telomere dysfunction [25,26]. We do not find evi-
dence for genomic amplification of regions involved in the
complex clusters found here. Therefore, we consider it
unlikely that these complex rearrangements are a result of
the breakage-fusion-bridge cycle. As outlined below, we
find that several complex clusters identified here resemble
the chromothripsis rearrangements described recently [21].
Clusters contain short and large chromosomal frag-
ments that have head and tail sides connected to other dis-
tant chromosomal fragments as exemplified for the cluster
involving chromosomes 15 and 20 in patient 3 (Figure 2d).
Furthermore, the inter- and intrachromosomal break-
points of this cluster and most other clusters (chromo-
somes 17 and 21, chromosomes 3 and 6, chromosome 13)
are associated with copy number changes (Additional file
7), leading to two copy number states: high for retained
fragments (that is, with head and tail sides connected to
other chromosomal fragments) and low for lost fragments
(no connection to other fragments) (Figure 2d). Such
alternating high and low copy number states are a striking
feature of chromothripsis clusters identified previously
[21]. However, the copy number changes we observed
were not always as pronounced as previously reported
[21]. This may be due to the fact that we studied heteroge-
neous tumor biopsies in our study as compared to clonally
derived homogeneous cell lines in the previous study.
For the clusters on chromosome 1 in patient 3, chro-
mosomes 3 and 6 in patient 4 and chromosomes 17 and
21 in patient 4, we observed that cluster boundaries
extend to telomeric regions (Additional file 8), repre-
senting another characteristic that has been described as
a hallmark of chromothripsis [21].
Based on sensitive PCR genotyping of breakpoints,
several chromothripsis clusters displayed exclusive pre-
sence in either the primary tumor or the metastasis
(Figure 2; Additional files 4, 9 and 10), further support-
ing the notion that they occurred as single simultaneous
events since a progressive model would more likely have
resulted in the presence of at least some of the break-
points in the corresponding lesion.
Capillary sequencing of PCR fragments across break-
points allowed us to determine sequence characteristics
of breakpoint regions. We characterized 159 fusion
points at nucleotide resolution (Additional file 11), of
which 69 fall within complex chromothripsis clusters.
There were no major differences in breakpoint character-
istics for rearrangements within or outside complex clus-
ters. Overall, we found that 38% were blunt-ended
fusions and another 40% contained several nucleotides of
microhomology, the majority of the fusion points having
microhomology of 1 to 3 bp. For 22% of fused segments
we observed insertions of short nucleotide stretches,
mostly below 6 bp, which likely represent non-templated
nucleotides, which are often seen for double-strand
breaks repaired by non-homologous end-joining [27,28].
Next, we determined the overlap of breakpoints with
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repeat annotation (long interspersed nuclear elements
(LINEs), short interspersed nuclear elements (SINEs),
long terminal repeat (LTR) retrotransposons, DNA
repeats). However, we could not identify significant asso-
ciation of somatic breakpoints with any of these repeat
classes when compared to a set of randomly sampled
positions across the genome (Fisher exact, P = 0.5). The
sequence characteristics of fusion points that we
observed here resemble those that have been detected in
various other cancers [12,14,15,19], and are in line with a
process of non-homologous end-joining-mediated repair
of double-strand DNA breaks [21,27,28].
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Figure 2 Examples of clusters of rearrangements in primary and metastatic tumor genomes. (a) A cluster of rearrangements involving
chromosomes 3 and 6 specific for the primary tumor of patient 4. (b) A cluster of rearrangements on chromosome 13, which could be found in
both the primary tumor and the liver metastasis of patient 1. (c) A metastasis-specific cluster of rearrangements involving chromosomes 17 and
21 of patient 4. Orientations of fusions are colored as in Figure 1. Red copy number plots and B allele frequencies correspond to the liver
metastasis and blue plots correspond to the primary tumor. Copy number variation and B allele frequencies for matching normal colon and liver
tissue are plotted in black. (d) Breakpoints and copy number changes involving a cluster of rearrangements on chromosomes 15 and 20 in the
primary tumor genome of patient 3. The upper panel shows a nucleotide-resolution map of fusion points for this cluster. Lines indicate fusions
between chromosomal fragments. Genomic coordinates indicate positions of breakpoints. Chromosomal fragments with both head and tail side
connected to other fragments are retained, while fragments that lack any link (fusion) are supposed to be deleted. This expected pattern of
retained and deleted fragments is reflected by the copy number profile for chromosome 15 (lower panel). BAF, B allele frequency.
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Overall, we conclude that small and large chromo-
thripsis events result from massive double-strand breaks
and are frequently occurring in primary and metastatic
colorectal cancer.
Chromothripsis clusters contribute to tumorigenesis in
conjunction with point mutations, copy number changes
and structural rearrangements
Recent studies have shown that complex rearrangements
may promote cancer progression through disruption of
tumor suppressor genes, or generation of fusion genes
[14,15,19,21]. In addition, cancer amplicons frequently
center on oncogenes, such as ERBB2 and MYC [18]. To
understand the contribution of chromothripsis clusters
to tumor growth and metastasis, we analyzed the break-
point regions for the presence of cancer genes. One
breakpoint of the cluster on chromosome 1 in patient 3
disrupts the fumarate hydratase gene (FH), which is a
tumor suppressor frequently mutated in renal cell can-
cer (Figure 3a) [29]. Another rearrangement in the same
cluster disrupts EXO1, which has tumor suppressor
activity and may act together with APC to promote gas-
trointestinal tumor formation [30]. In patient 1, we
identified a cluster on chromosome 13, and one of the
breakpoints disrupts MYCBP2 (Figure 3b). In addition,
there are several cancer related genes from the Cancer
Gene Census within the boundaries of this cluster and
these may be affected by one of the numerous rearran-
gements in this cluster [31]. Besides complex clusters,
we identified a range of isolated structural rearrange-
ments for which breakpoints affect cancer genes, such
as NOTCH2, FHIT, MLL3 and ETV6 (Additional file 4)
[31]. We also detected several genes that form hotspots
of rearrangements in several patients (Additional file
12). For example, PARK2 is a tumor suppressor gene
known to contain frequent deletions in colorectal can-
cers [32]. We identified several independent deletions of
PARK2 in primary and metastatic tumors of patients 3
and 4. Although PARK2 lies in a common fragile site,
which explains the frequent deletions in this gene, it
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Figure 3 Cancer-related genes affected by rearrangements breakpoints. (a) Disruption of EXO1 and FH (fumarate hydratase) by
rearrangement breakpoints in a metastasis-specific cluster on chromosome 1 in patient 3. (b) Disruption of MYCBP2 by a rearrangement
breakpoint in a cluster on chromosome 13 in patient 1. Genes from the Cancer Genome Census are also depicted for this cluster. (c) Disruption
of SORBS2 by metastasis-specific deletions in patients 2 and 4. (d) Disruption of CSMD1 by a metastasis-specific deletion in patient 2.
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may function as a tumor suppressor and disruption of
Park2 increases adenoma development in Apc mutant
mice [32,33]. Interestingly, patient 4 carries two inde-
pendent APC point mutations in the primary tumor and
the metastasis, respectively (see below; Table 2). We
also identified several independent rearrangements in
FHIT, WWOX, PRKG1 and MACROD2 in multiple
patients. All of these genes are located at common fra-
gile sites and have been found to contain rearrange-
ments in several cancers [12,34].
Table 2 Point mutations identified in the cancer mini-exome of patients 1 to 4
Patient 1 Patient 2 Patient 3 Patient 4
Gene TC LM TC LM TC LM TC LM
APC 5:112175523 T/- 5:112175523 T/- E1536*
(5:1121758970)
E1536*
(5:1121758970)
Y1376*
(5:112175419)
Y1376*
(5:112175419)
5:112128152
C/-
R499*
(5:112162891)
R876*
(5:112173917)
R876*
(5:112173917)
DDR2 H340D
(1:162731163)
KRAS G12A
(12:25398284)
G12A
(12:25398284)
G12A
(12:25398284)
PTPRF D562G
(1:44058144)
D562G
(1:44058144)
SMAD2 R321*
(18:45374882)
SMAD4 L495P
(18:48604662)
TP53 R273C
(17:7577121)
R273C
(17:7577121)
R175H
(17:7578406)
C275W
(17:7577113)
MLL3 I155T
(7:152012349)
I155T
(7:152012349)
PARP14 Q1332P
(3:122437236)
Q1332P
(3:122437236)
PIK3CA E545K (3:
178936091)
E545K (3:
178936091)
E545K (3:
178936091)
KDR R1032*
(4:55956221)
PRKCD T419I
(3:53220352)
RFC1 4:39290432 T/C
EXOC4 K765R
(7:133682332)
TSC1 R288C
(9:135787720)
FGFR2 R399*
(10:123274723)
R399*
(10:123274723)
NUP98 H1647D
(11:3704460)
H1647D
(11:3704460)
ERBB3 V104M
(12:56478854)
V104M
(12:56478854)
RASA3 V117M
(13:114806499)
DNAH9 R4106H
(17:11837216)
TAOK1 K484M
(17:27835026)
K484M
(17:27835026)
ATRX X:76845412 +A
TTN K13350N
(2:179445230)
H8533Y
(2:179571272)
E4246K
(2:179604510)
EPHA4 2:222298957 +T
TC, colon tumor; LM, liver metastasis. Genomic coordinates are based on the hg19 genome build.
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To gain insight into the contribution of point mutations
to tumor development in these and other cancer-rele-
vant genes in our tumor samples, we performed next-
generation sequencing-based mutational profiling of a
cancer mini-exome in all 16 tumor and control samples
(1, 296 genes; Materials and methods). We found cano-
nical disrupting mutations in APC, TP53, SMAD2 and
SMAD4 as well as KRAS (G12A) activation in several
patients (Table 2) [1]. For patient 2 we identified the
same mutations in KRAS, APC and PTPRF in both pri-
mary and metastatic tumors. However, mutations in
SMAD2 and SMAD4 could only be detected in DNA
from the metastatic tissue. In contrast, the tumor gen-
omes of patient 4 contained mutations in APC, KRAS
and TP53, but both primary tumor and metastasis car-
ried their own private mutations in these genes. These
data complement the mate-pair and copy number data,
which also show overlapping mutations but also many
distinct genetic variations in primary and metastatic
samples, which may affect cancer genes in a lesion-spe-
cific manner (Figure 1c). For example, we identified
metastasis-specific recurrent deletions of CASP3 and
SORBS2 or deletion of CSMD1 (Figure 3c, d) [35,36].
Interestingly, SORBS2, which is also known as ArgBP2,
is repressed during oncogenic transformation of the
pancreas and the protein was implicated in cell adhesion
and migration [36]. Furthermore, CSMD1 mutations
have been found particularly in advanced colorectal
tumors, suggesting a role in metastasis formation [35].
Therefore, the distinct genetic changes in metastastic
samples compared to corresponding primary tumors
likely contribute to metastasis formation or provide
advantage to tumor growth at metastatic sites (liver).
These data emphasize that comprehensive genetic
analysis at the nucleotide as well as structural level of
both primary tumor and metastasis is needed to outline
an effective targeted treatment strategy for colorectal
cancer.
Conclusions
Our data show that clusters of complex genomic rearran-
gements occur frequently in primary and metastatic col-
orectal tumors. Based on the features of these complex
rearrangement clusters, we find that chromothripsis is a
common driver of genetic changes in colorectal cancer.
We conclude that complex chromothripsis events in con-
junction with simple copy number changes and point
mutations shape the dynamic architecture of colorectal
cancer genomes and all together provide the genetic
basis for tumor growth and metastasis. Therefore, the
impact of chromothripsis on tumor development and
evolution may be greater than previously anticipated [21].
The molecular mechanisms that drive chromothripsis
are unclear, but the characteristics of break points
suggest that chromosome shattering occurred randomly,
yet regionally, as a result of double-strand breaks and
that chromosomal fragments are likely repaired by non-
homologous end-joining [21,24]. If the reshuffling of
genetic information poses any benefit to the cell, chro-
mothripsis clusters may drive tumor formation and
metastases. A complex cluster could also be a passive
genetic event - for example, when coinciding with a
growth promoting mutation in the same cell. While the
observation that some complex clusters are uniquely
present in primary or metastatic lesions could be sup-
portive of this hypothesis, it could also be that chromo-
thripsis events provide a selective advantage specific for
the molecular environment of either the primary tumor
or the metastasis.
The distinct genetic mutation patterns in primary and
metastatic tumors, illustrate the need for much more
comprehensive screening of cancer genomes than is cur-
rently common practice, including profiling of (com-
plex) structural changes along with coding mutations in
primary and metastatic lesions.
Materials and methods
Samples
The research in this study conformed to the Declaration
of Helsinki of the World Medical Association concern-
ing human material/data and experimentation. The
Medical Ethics Committee (METC) of the University
Medical Centre Utrecht, The Netherlands approved the
genetic analysis of DNA from tumor and normal tissues
of the patients described in this paper. Tissue samples
were previously acquired as part of a series of routine
diagnostic and pathological analyses in our hospital.
We performed mate-pair sequencing on DNA from
tumor biopsies and control samples from four patients
with colorectal adenocarcinoma attending University
Medical Center Utrecht, The Netherlands. For each
patient, we obtained DNA from the primary colon
tumor, normal colon tissue, liver metastasis and normal
liver tissue. We assessed tumor content of biopsies by
microscopic analysis of stained cryosections (tumor con-
tent > 80%).
Preparation of mate-pair libraries and SOLiD sequencing
Mate-paired libraries were generated from 50 to 100 μg
DNA isolated from tumor and control samples. Mate-
pair library preparation was essentially as described in
the SOLiDv3.5 library preparation manual (Applied Bio-
systems, Carlsbad, California, USA). We performed two
genomic DNA size selections per library: one after
shearing and one after CAP adaptor ligation. Libraries
were cloned and 384 clones per library were picked for
capillary sequencing to assess the presence of adaptors,
insert sizes and chimeric molecules. Chimeric molecules
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were identified based on a tag distance > 100 kb. On
average, we observed between 5% and 15% present chi-
meric molecules per library. We sequenced 2× 50-bp
mates for each library on one or two quadrants of a
SOLiD V4 sequencing slide. Mate-pair sequencing data
are available from the Sequence Read Archive of the
European Nucleotide Archive (ENA SRA) under acces-
sion number [SRA:ERP000875].
Bioinformatic analysis of mate-pair reads
The F3 and R3 mate-pair tags were mapped indepen-
dently to the human reference genome (GRCh37/hg19)
using BWA software V0.5.0 with the following settings:
-c -l 25 -k 2 -n 1 [37]. Mate-pair tags with unambiguous
mapping were combined and split into local (< 100 kb)
and remote (> 100 kb) mate-pair sets. Local mate-pairs
were further split into mate-pairs with normal orienta-
tion of the tags relative to each other, mate-pairs with
inverted tags and mate-pairs with everted tags [24].
Deletions were called from local mate-pairs with correct
orientation and with a mate-pair span in the top 0.5% per-
centile of the mate-pair size distribution. Tandem duplica-
tions were called from local mate-pairs with everted
orientation and inversions were called from local mate-
pairs with inverted orientation. Mate-pairs were clustered
based on overlapping mate-pairs with a maximal tag dis-
tance of two times the average library insert size. The
remote (inter-chromosomal and intra-chromosomal > 100
kb) mate-pairs were clustered independently of the relative
orientation of the mate-pair tags. The orientation of the
different mate-pair tags in a cluster relative to each other
is indicated by H (or h for the minus strand) when the tag
has its ‘head’ side (the side that points towards the start of
the chromosome) opposed to the pairing tag and T (or t
for the minus strand) when a tag has its ‘tail’ side (the side
that points towards the end of the chromosome) opposed
to the pairing tag. Mate-pair clustering was performed per
patient (four samples) and tumor-specific rearrangements
were selected based on clusters without overlapping mate-
pairs derived from normal tissue samples. Tumor-specific
rearrangements were confirmed by PCR across the break-
point in primary tumor, metastasis and normal liver and
colon samples. Rearrangement fusion points were visua-
lized by Circos software [38].
SNP array analysis
DNA from all 16 tumor and control samples was analyzed
by Illumina Cyto12 SNP arrays according to standard pro-
cedures (Illumina, San Diego, California, USA). Copy
number changes and allelic profiles were derived from log
R ratios and B allele frequencies that are provided by the
Illumina Genomestudio package. Since overall copy num-
ber changes in the heterogeneous samples that we ana-
lyzed are not as marked as in clonally derived cell lines, we
used custom scripts to detect areas with low or high log R
ratio values (increase in copy number is defined as: a posi-
tive shift (> 0.1) in average log R ratio compared to a con-
trol sample (healthy colon or liver tissue from the same
patient), and a decrease in copy number is defined as a
negative shift (> 0.1) in log R ratio compared to the con-
trol sample. For both positive and negative changes, we
required at least 12 consecutive deviating probes, while
allowing a maximum of 2 probes that do not meet the cri-
terion. Copy number changes were further substantiated
by changes in average B allele frequency for heterozygous
positions relative to control samples (average B allele fre-
quency shift > 0.05, also found in a minimum of 12
sequential probes, including a 2 probe ‘mismatch’ cutoff).
The resulting copy variable regions were manually curated
based on B allele frequency plots and log R ratio plots of
tumors and matching healthy samples. SNP array data
were submitted to the National Center for Biotechnology
Information Gene Expression Omnibus archive and are
available under accession number [GEO:GSE32711].
Mutational profiling
Mutational analysis of 1, 296 kinases and cancer-related
genes was performed by multiplexed enrichment of bar-
coded fragment libraries from all 16 samples [39]. Cap-
turing was done using a custom-designed Agilent 244K
array with 60-mer tiled probes on both strands [40].
The pool of enriched libraries was sequenced on one
slide of a SOLiD3.5 instrument. Data were mapped to
the reference genome (GRCh37/hg19) using BWA (-c -l
25 -k 2 -n 1). SNP calling was done using a custom ana-
lysis pipeline that identifies mutations with a non-refer-
ence allele frequency larger than 15% and a coverage of
at least 10×. Sequencing data are available from the
Sequence Read Archive of the European Nucleotide
Archive (ENA SRA) under accession number [SRA:
ERP000875]. All identified variants were validated by
PCR and capillary sequencing.
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Additional file 1: A flow-diagram of the procedure for detecting
tumor-specific rearrangements.
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Additional file 3: Table with SOLiD sequencing statistics of mate-
pair libraries from tumor samples and healthy tissues.
Additional file 4: Table with all tumor-specific structural
rearrangements identified by mate-pair sequencing in the four
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Additional file 5: Size distribution of tumor-specific deletions in
four patients.
Additional file 6: Three examples of clusters of rearrangements in
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Additional file 7: Copy number changes coinciding with
breakpoints of rearrangement clusters.
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Additional file 8: Log R ratios and B allele frequencies for
chromosomes affected by chromothripsis.
Additional file 9: PCR gel of genomic rearrangements within
clusters on chromosomes 17 and 21 and chromosomes 3 and 6.
Additional file 10: Table indicating the presence of complex
rearrangement clusters in primary and metastatic tumors.
Additional file 11: Sequence characteristics of tumor-specific fusion
points.
Additional file 12: Hotspots of rearrangements in PARK2 and
MACROD2.
Abbreviations
bp: base pair; PCR: polymerase chain reaction; SNP: single-nucleotide
polymorphism.
Acknowledgements
This work was financially supported by the Cancer Genomics Center (CGC)
program of the Netherlands Genomics Initiative (NGI). We thank Martin Poot
for critically reading the manuscript.
Author details
1Department of Medical Genetics, University Medical Center Utrecht,
Universiteitsweg 100, Utrecht, 3584 CG, The Netherlands. 2Department of
Medical Oncology, University Medical Center Utrecht, Universiteitsweg 100,
Utrecht, 3584 CG, The Netherlands. 3Hubrecht Institute KNAW and University
Medical Center Utrecht, Uppsalalaan 8, Utrecht, 3584 CT, The Netherlands.
Authors’ contributions
WK conceived and designed the study and performed the experiments and
bioinformatic analysis and wrote the paper. MH performed bioinformatic
analysis of array data. OP performed the breakpoint sequencing and
analyzed the data. MT generated mate-pair libraries. IR performed SOLiD
sequencing and generated fragment libraries. JV designed the study and
contributed patient material. MR performed analysis of mate-pair sequencing
data. SL performed analysis of targeted-exome sequencing data. IN
performed analysis of targeted-exome sequencing data and designed the
capture array. WR performed breakpoint sequencing. RS performed SNP
array analysis. JB generated mate-pair libraries. VG performed analysis of
mate-pair sequencing data. MK analyzed breakpoint regions and supervised
experiments. EV conceived and supervised the study and wrote the paper.
EC conceived, designed and supervised the study and wrote the paper.
Competing interests
The authors declare that they have no competing interests.
Received: 21 July 2011 Revised: 11 October 2011
Accepted: 19 October 2011 Published: 19 October 2011
References
1. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: Molecular
basis of colorectal cancer. N Eng J Med 2009, 361:2449-2460.
2. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G,
Davies H, Teague J, Butler A, Stevens C, Edkins S, O’Meara S, Vastrik I,
Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B,
Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K,
Hinton J, Jenkinson A, Jones D, et al: Patterns of somatic mutation in
human cancer genomes. Nature 2007, 446:153-158.
3. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D,
Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P,
Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L,
Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B,
Kinzler KW, Velculescu VE: The consensus coding sequences of human
breast and colorectal cancers. Science 2006, 314:268-274.
4. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D,
Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V,
Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z,
Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K,
Park BH, Pethiyagoda CL, Pant PV, et al: The genomic landscapes of
human breast and colorectal cancers. Science 2007, 318:1108-1113.
5. Stratton MR: Exploring the genomes of cancer cells: progress and
promise. Science 2011, 331:1553-1558.
6. McDermott U, Downing JR, Stratton MR: Genomics and the continuum of
cancer care. N Eng J Med 2011, 364:340-350.
7. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T,
Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B,
Willis J, Markowitz SD: Comparative lesion sequencing provides insights
into tumor evolution. Proc Natl Acad Sci USA 2008, 105:4283-4288.
8. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD,
Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC,
Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF,
Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K,
Davies S, Guintoli T, et al: Genome remodelling in a basal-like breast
cancer metastasis and xenograft. Nature 2010, 464:999-1005.
9. Klein CA: Parallel progression of primary tumours and metastases. Nat
Rev Cancer 2009, 9:302-312.
10. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH,
Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-
Donahue CA: Distant metastasis occurs late during the genetic evolution
of pancreatic cancer. Nature 2010, 467:1114-1117.
11. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A,
Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G,
Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G,
Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M,
Marra MA, Aparicio S: Mutational evolution in a lobular breast tumour
profiled at single nucleotide resolution. Nature 2009, 461:809-813.
12. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA,
Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-
Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW: The patterns
and dynamics of genomic instability in metastatic pancreatic cancer.
Nature 2010, 467:1109-1113.
13. Campbell PJ, Stephens PJ, Pleasance ED, O’Meara S, Li H, Santarius T, Stebbings LA,
Leroy C, Edkins S, Hardy C, Teague JW, Menzies A, Goodhead I, Turner DJ,
Clee CM, Quail MA, Cox A, Brown C, Durbin R, Hurles ME: Identification of
somatically acquired rearrangements in cancer using genome-wide massively
parallel paired-end sequencing. Nat Genet 2008, 40:722-729.
14. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT,
Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C,
Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C,
Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE,
Foekens JA, Reis-Filho JS, van ‘t Veer L, Richardson AL, Børresen-Dale AL,
et al: Complex landscapes of somatic rearrangement in human breast
cancer genomes. Nature 2009, 462:1005-1010.
15. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY,
Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K,
Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D,
Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K,
Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, et al: The genomic
complexity of primary human prostate cancer. Nature 2011, 470:214-220.
16. Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, Tsutsumi S,
Sonoda K, Totsuka H, Shirakihara T, Sakamoto H, Wang L, Ojima H,
Shimada K, Kosuge T, Okusaka T, Kato K, Kusuda J, Yoshida T, Aburatani H,
Shibata T: High-resolution characterization of a hepatocellular carcinoma
genome. Nat Genet 2011, 43:464-469.
17. Myllykangas S, Knuutila S: Manifestation, mechanisms and mysteries of
gene amplifications. Cancer Lett 2006, 232:79-89.
18. Bignell GR, Santarius T, Pole JC, Butler AP, Perry J, Pleasance E, Greenman C,
Menzies A, Taylor S, Edkins S, Campbell P, Quail M, Plumb B, Matthews L,
McLay K, Edwards PA, Rogers J, Wooster R, Futreal PA, Stratton MR:
Architectures of somatic genomic rearrangement in human cancer
amplicons at sequence-level resolution. Genome Res 2007, 17:1296-1303.
19. Hillmer AM, Yao F, Inaki K, Lee WH, Ariyaratne PN, Teo AS, Woo XY,
Zhang Z, Zhao H, Ukil L, Chen JP, Zhu F, So JB, Salto-Tellez M, Poh WT,
Zawack KF, Nagarajan N, Gao S, Li G, Kumar V, Lim HP, Sia YY, Chan CS,
Leong ST, Neo SC, Choi PS, Thoreau H, Tan PB, Shahab A, Ruan X, et al:
Comprehensive long-span paired-end-tag mapping reveals characteristic
patterns of structural variations in epithelial cancer genomes. Genome
Res 2011, 21:665-675.
Kloosterman et al. Genome Biology 2011, 12:R103
http://genomebiology.com/2011/12/10/R103
Page 10 of 11
20. Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S: Chromothripsis
identifies a rare and aggressive entity among newly diagnosed multiple
myeloma patients. Blood 2011, 118:675-678.
21. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ,
Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML,
McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP,
Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA,
Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR,
et al: Massive genomic rearrangement acquired in a single catastrophic
event during cancer development. Cell 2011, 144:27-40.
22. Medvedev P, Stanciu M, Brudno M: Computational methods for
discovering structural variation with next-generation sequencing. Nat
Methods 2009, 6:S13-20.
23. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A,
Lee C, McKernan K, De La Vega FM, Kinzler KW, Vogelstein B, Diaz LA Jr,
Velculescu VE: Development of personalized tumor biomarkers using
massively parallel sequencing. Sci Transl Med 2010, 2:20ra14.
24. Kloosterman WP, Guryev V, van Roosmalen M, Duran KJ, de Bruijn E,
Bakker SC, Letteboer T, van Nesselrooij B, Hochstenbach R, Poot M,
Cuppen E: Chromothripsis as a mechanism driving complex de novo
structural rearrangements in the germline. Hum Mol Genet 2011,
20:1916-1924.
25. O’Hagan RC, Chang S, Maser RS, Mohan R, Artandi SE, Chin L, DePinho RA:
Telomere dysfunction provokes regional amplification and deletion in
cancer genomes. Cancer Cell 2002, 2:149-155.
26. Artandi SE, DePinho RA: Telomeres and telomerase in cancer.
Carcinogenesis 2010, 31:9-18.
27. Lieber MR: The mechanism of double-strand DNA break repair by the
nonhomologous DNA end-joining pathway. Annu Rev Biochem 2010,
79:181-211.
28. Simsek D, Jasin M: Alternative end-joining is suppressed by the canonical
NHEJ component Xrcc4-ligase IV during chromosomal translocation
formation. Nat Struct Mol Biol 2010, 17:410-416.
29. Alam NA, Olpin S, Rowan A, Kelsell D, Leigh IM, Tomlinson IP, Weaver T:
Missense mutations in fumarate hydratase in multiple cutaneous and
uterine leiomyomatosis and renal cell cancer. J Mol Diagn 2005,
7:437-443.
30. Kucherlapati M, Nguyen A, Kuraguchi M, Yang K, Fan K, Bronson R, Wei K,
Lipkin M, Edelmann W, Kucherlapati R: Tumor progression in Apc(1638N)
mice with Exo1 and Fen1 deficiencies. Oncogene 2007, 26:6297-6306.
31. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS: A census of
amplified and overexpressed human cancer genes. Nat Rev Cancer 2010,
10:59-64.
32. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K,
Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ: PARK2 deletions occur
frequently in sporadic colorectal cancer and accelerate adenoma
development in Apc mutant mice. Proc Natl Acad Sci USA 2010,
107:15145-15150.
33. Drusco A, Pekarsky Y, Costinean S, Antenucci A, Conti L, Volinia S,
Aqeilan RI, Huebner K, Zanesi N: Common fragile site tumor suppressor
genes and corresponding mouse models of cancer. J Biomed Biotechnol
2011, 2011:984505.
34. Smith DI, McAvoy S, Zhu Y, Perez DS: Large common fragile site genes
and cancer. Sem Cancer Biol 2007, 17:31-41.
35. Farrell C, Crimm H, Meeh P, Croshaw R, Barbar T, Vandersteenhoven JJ,
Butler W, Buckhaults P: Somatic mutations to CSMD1 in colorectal
adenocarcinomas. Cancer Biol Ther 2008, 7:609-613.
36. Taieb D, Roignot J, Andre F, Garcia S, Masson B, Pierres A, Iovanna JL,
Soubeyran P: ArgBP2-dependent signaling regulates pancreatic cell
migration, adhesion, and tumorigenicity. Cancer Res 2008, 68:4588-4596.
37. Li H, Durbin R: Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 2009, 25:1754-1760.
38. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ,
Marra MA: Circos: an information aesthetic for comparative genomics.
Genome Res 2009, 19:1639-1645.
39. Nijman IJ, Mokry M, van Boxtel R, Toonen P, de Bruijn E, Cuppen E:
Mutation discovery by targeted genomic enrichment of multiplexed
barcoded samples. Nat Methods 2010, 7:913-915.
40. Mokry M, Feitsma H, Nijman IJ, de Bruijn E, van der Zaag PJ, Guryev V,
Cuppen E: Accurate SNP and mutation detection by targeted custom
microarray-based genomic enrichment of short-fragment sequencing
libraries. Nucleic Acids Res 2010, 38:e116.
doi:10.1186/gb-2011-12-10-r103
Cite this article as: Kloosterman et al.: Chromothripsis is a common
mechanism driving genomic rearrangements in primary and metastatic
colorectal cancer. Genome Biology 2011 12:R103.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kloosterman et al. Genome Biology 2011, 12:R103
http://genomebiology.com/2011/12/10/R103
Page 11 of 11
